Generative AI Gains Traction in Life Sciences Marketing, ZS Survey Finds

Generative AI is gaining momentum in life sciences marketing, evolving from isolated experiments to more structured pilots and early adoption. According to a 2024 survey by ZS of nearly 80 marketing leaders, use of generative AI for professional purposes has more than doubled since 2023, though widespread adoption remains limited—particularly among mid-level marketers. Content creation remains a top priority,

Become a Member

Members have access to all articles.

Membership
with companies piloting tools for faster campaign ideation and derivative asset production. Some organizations are also exploring AI-driven approaches to medical-legal review and insight mining by integrating structured and unstructured data sources. However, scaling these efforts often requires rethinking workflows, operating models, and talent strategies to move from experimentation to execution.

Despite growing interest, ZS found that many marketing leaders remain hesitant to adopt generative AI at scale, citing concerns around return on investment, operational disruption, and internal readiness. Early adopters are addressing these barriers through hands-on experimentation, internal capability-building, and more integrated workflows. A key shift in 2025 is the move from viewing generative AI as a set of tools to treating it as part of a broader, interconnected marketing ecosystem. As organizations aim to capture value beyond individual pilots, the focus is turning to leadership alignment, cross-functional collaboration, and redefining the marketer’s role in an AI-enabled environment.

Read more